Opioid overdose emergency treatment
Search documents
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
Globenewswire· 2025-12-22 13:05
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®. As ...
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
Globenewswire· 2025-03-06 12:40
Core Viewpoint - Scienture Holdings, Inc. has entered into a definitive agreement with Summit Biosciences for the exclusive U.S. rights to launch REZENOPY, a naloxone HCl nasal spray, aimed at addressing the opioid overdose crisis [1][4]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on developing and distributing novel specialty pharmaceutical products to meet unmet market needs [11]. - Scienture, LLC is a specialty pharmaceutical company with a team dedicated to bringing unique products to market [11]. Product Details - REZENOPY (naloxone HCl) Nasal Spray 10mg is the most potent version of naloxone available, designed for emergency treatment of opioid overdose [3][7]. - The product is intended for intranasal use and is supplied in a carton containing two blister packages, each with a single spray device [7]. Collaboration and Manufacturing - Kindeva Drug Delivery will manufacture and supply REZENOPY, while Scienture will own the new drug application and handle sales, marketing, and distribution in the U.S. [2]. - This collaboration is seen as a strategic step to enhance public health initiatives and improve access to life-saving interventions for those at risk of opioid overdose [4][6]. Market Context - The nasal delivery of naloxone HCl is recognized for its efficacy and ease of use, making it a vital tool for first responders and healthcare providers [5]. - According to IQVIA data, the total annual sales for naloxone in the U.S. market reached $189 million, with a unit volume of 10 million [5].